Newsletter

Menu

Merck posts upbeat Q2 results

By Staff Correspondent |

Pharma giant Merck (MRK) reported a 12.4% dip in earnings for the second quarter as higher costs offset a dip in income taxes. While R&D expenses rose 28%, materials and production costs witnessed a hike of 10%. The top and bottom line came in above analysts’ expectations. Following this, shares of the company rose 1.39% in premarket trading.

Earnings for the quarter declined 12.4% to $1.71 billion or $0.63 per share. The results included acquisition and divestiture related costs, and restructuring costs. Non-GAAP EPS increased 5% to $1.06.

Worldwide sales rose 5% to $10.5 billion, including a 1% positive impact from foreign exchange. The top line was driven by an 89% jump in sales of the cancer drug Keytruda, and a 30% climb in sales of cervical cancer preventing therapy Gardasil.

For the full year of 2018, Merck narrowed its revenue outlook to the range of $42 billion to $42.8 billion from the previous estimate of $41.8 billion to $43 billion. GAAP EPS target is trimmed down to a range of $2.51-$2.59 from $2.45-$2.57 while non-GAAP EPS outlook is lifted to a range of $4.22-$4.30 from $4.16-$4.28.

Merck Q2 2018 earnings results
Merck Q2 2018 Earnings Infographics

Pharmaceutical sales grew 6%, driven primarily by growth in oncology, vaccines, and hospital acute care. This was partially offset by lower sales in virology and the ongoing impacts of the loss of market exclusivity for several products.

Oncology benefited from an increase in sales of Keytruda, which reflects its continued launches with new indications globally and the strong momentum for the treatment of patients with non-small cell lung cancer, as Keytruda is the only anti-PD-1 approved in the first-line setting.

Animal Health sales increased 14% fuelled by higher sales of livestock products. The growth was also driven by higher sales of companion animal products, specifically from the Bravecto line of products that kill fleas and ticks in dogs and cats for up to 12 weeks.

R&D expenses increased 28% due to a $344 million charge for the Viralytics acquisition, increased clinical development spending, in particular from oncology collaborations, as well as investment in early drug development.

Related: Merck joins pharma giants in lowering drug prices

For the third quarter, Merck will be facing a decline in six of its drug prices by 10% or more. This move by Merck follows that of Pfizer (PFE) and Swiss firm Novartis, who agreed to freeze the price increase for this year after President Donald Trump’s Twitter outburst.

Meanwhile, Merck’s rival Pfizer is expected to report its second-quarter results on July 31. Analysts are expecting Pfizer to post a 10.40% jump in earnings for the second quarter on a 3.20% rise in revenue.

Shares of Merck ended Thursday’s regular trading session down 0.74% at $64.01 on the NYSE.

Related Infographics: Q1 Earnings

Advertisement

More on this Company

51 responses to “Merck posts upbeat Q2 results”

  2. esports

    […]Wonderful story, reckoned we could combine a few unrelated data, nonetheless seriously worth taking a search, whoa did 1 study about Mid East has got extra problerms at the same time […]

  4. french bulldog rescue

    […]although websites we backlink to below are considerably not related to ours, we feel they are essentially worth a go as a result of, so have a look[…]

  13. linh hoang

    […]Wonderful story, reckoned we could combine a couple of unrelated information, nevertheless definitely really worth taking a appear, whoa did a single discover about Mid East has got much more problerms at the same time […]

  19. dog probiotic

    […]just beneath, are several totally not related web pages to ours, on the other hand, they’re surely worth going over[…]

  20. dr kim acupuncture

    […]Wonderful story, reckoned we could combine a few unrelated information, nonetheless seriously worth taking a search, whoa did one understand about Mid East has got additional problerms too […]

  29. wix seo

    […]that would be the finish of this report. Here you’ll obtain some web-sites that we feel you will value, just click the links over[…]

  38. french pitbull

    […]Wonderful story, reckoned we could combine a handful of unrelated information, nonetheless genuinely really worth taking a search, whoa did one particular discover about Mid East has got extra problerms also […]

  46. elizabeth kerr

    […]although internet sites we backlink to below are considerably not associated to ours, we feel they are truly really worth a go via, so possess a look[…]

  47. yorkie poo breeding

    […]that will be the finish of this article. Here you will locate some websites that we assume you’ll appreciate, just click the links over[…]

  50. chile candies

    […]check beneath, are some entirely unrelated internet sites to ours, on the other hand, they are most trustworthy sources that we use[…]

Top